Latest Innovation News

Cann Group Limited has successfully completed a significant debt restructure and equity raising, improving its financial footing and liquidity to support future growth.

Neuren Pharmaceuticals’ partner Acadia secures FDA approval for DAYBUE STIX, a new powder formulation of trofinetide offering greater flexibility for Rett syndrome patients. This milestone expands treatment options and sets the stage for increased royalty revenue in 2026.

Fortifai Limited introduces Nol8, a breakthrough platform that processes data in real time with millisecond latency, promising to transform industries reliant on massive data flows.

Fortifai Limited has acquired an exclusive license to Nol8, a breakthrough real-time data processing technology developed by the Technion. This acquisition positions Fortifai to revolutionize data handling across gaming, AI, finance, and cybersecurity sectors.

Loyal Metals has intersected 60 metres of rich chalcocite copper mineralisation near the surface at its Highway Reward Project, confirming the presence of extensive copper-gold deposits and advancing exploration efforts with a third drill underway.

Rio Tinto has completed due diligence on Calix’s Zesty Green Iron Demonstration Project, unlocking an initial $3 million investment and moving the venture closer to commercial reality.

Biome Australia has initiated its first human clinical trial for the proprietary probiotic strain Lactobacillus plantarum BMB18, aiming to validate its benefits for digestive and mood-related symptoms.

Imricor Medical Systems has secured Institutional Review Board approval for the University of Virginia Health to join its VISABL-AFL clinical trial, marking a key expansion in the US. Procedures are set to begin early next year, supporting Imricor’s progress toward FDA approval and commercialisation.

Proteomics International's PromarkerD blood test shows clinically meaningful accuracy in predicting diabetic kidney disease among Aboriginal Australians, matching performance in non-Indigenous populations. This advancement offers a promising tool for early intervention in a high-risk group.

Aurora Labs has signed a landmark MOU with European defence giant MBDA to explore integrating its 3D-printed turbojet engines into advanced missile systems, marking a significant step into international defence markets.

Group One Capital has finalized a structured funding facility for the 107-unit Ahlie residential development in Canberra, setting the stage for milestone-driven revenue of up to $6 million over the project lifecycle.

Elevate Uranium has successfully assembled its U-pgrade™ Demonstration/Pilot Plant in Namibia, with steady state operations expected to start in January 2026. This milestone aims to validate a proprietary beneficiation process that could transform uranium processing economics.